TARS Short Interest Eases, But Bears Hold Ground Before Q3 Print
Tarsus Pharmaceuticals carries a relatively light short position compared with several of its closest Nasdaq peers heading into Thursday's earnings release. Short interest at 13.9% of free float is meaningful, but ARVN…